HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor

Hyeyeon Chang1,2, Yong-Won Shin1,3,4, Bhumsuk Keam5, Miso Kim5, Seock-Ah Im5 & Soon-Tae Lee1

1Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea
2Department of Neurology, Konyang University Hospital, Deajeon, Republic of Korea
3Center for Hospital Medicine, Seoul National University Hospital, Seoul, Republic of Korea
4Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea
5Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

Correspondence
Soon-Tae Lee, Department of Neurology, Integrated Cancer Care Center, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea. Tel: +82-2-2072-4757; Fax: +82-2-2072-4757, E-mail: staelee@snu.ac.kr

Funding Information
National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, ICT & Future Planning, Republic of Korea: 2019R1A2C1009003.

Received: 29 April 2020; Revised: 26 August 2020; Accepted: 12 September 2020

Annals of Clinical and Translational Neurology 2020; 7(11): 2243–2250
doi: 10.1002/acn3.51213

Abstract

Objective: While immune checkpoint inhibitors are increasingly used for various cancers, unpredictable immune-related adverse events (irAEs) such as autoimmune encephalitis is life-threatening. Here, we report an association between human leukocyte antigen (HLA) and atezolizumab-induced encephalitis.

Methods: From an institutional prospective cohort for encephalitis, we identified patients with autoimmune encephalitis after the use of atezolizumab, a PD-L1 (programmed death-ligand 1) inhibitor, from August 2016 to September 2019 and analyzed their HLA genotypes.

Results: A total of 290 patients received atezolizumab, and seven patients developed autoimmune encephalitis, and five of whom were enrolled for the analysis. The patients presented altered mentality, seizures, or myelitis. Three patients had the HLA-B*27:05 genotype in common (60%), which is significantly frequent given its low frequency in the general population (2.5%). After Bonferroni correction, HLA-B*27:05 was significantly associated with autoimmune encephalitis by atezolizumab (corrected P < 0.001, odds ratio 59, 95% CI = 9.0 ~ 386.9).

Interpretation: Here we found that three in five patients with autoimmune encephalitis associated with atezolizumab had the rare HLA-B*27:05 genotype. Further systematic analyses in larger cohorts are necessary to investigate the value of HLA screening to prevent the life-threatening adverse events.

Introduction

Immune checkpoint inhibitors (ICPIs) are increasingly used as an effective immune-based cancer therapy option in many types of solid and hematologic cancers. These drugs inhibit immune checkpoints on the effector T cell or tumor side, such as CTLA-4, PD-1, and PD-L1. However, by activating effector T cells and recognizing autoantigens, ICPIs can cause immune-related adverse events (irAEs), such as inflammation in the gastrointestinal tract, endocrine glands, skin, lung, liver, and nervous system. Guillian–Barre syndrome, myasthenia gravis, and aseptic meningitis are known irAEs in the general population (2.5%). After Bonferroni correction, HLA-B*27:05 was significantly associated with autoimmune encephalitis by atezolizumab (corrected P < 0.001, odds ratio 59, 95% CI = 9.0 ~ 386.9).

Interpretation: Here we found that three in five patients with autoimmune encephalitis associated with atezolizumab had the rare HLA-B*27:05 genotype. Further systematic analyses in larger cohorts are necessary to investigate the value of HLA screening to prevent the life-threatening adverse events.

The exact mechanism by which some patients develop encephalitis, a serious CNS-irAE, and the patients who are at a high risk for this complication remain unknown. Atezolizumab is a PD-L1 inhibitor approved for non-small-cell lung cancer, urethral carcinoma, and advanced triple-negative breast cancer. Although the incidence of irAEs caused by atezolizumab is lower than that caused by other ICPIs, several serious encephalitis cases have been reported after the use of atezolizumab. However, no known risk factors for irAEs were identified. Recently, we observed five consecutive patients with encephalitis caused by atezolizumab and found that they have a unique human leukocyte antigen (HLA) genotype. Here, we show evidence that HLA is likely a risk factor for encephalitis caused by atezolizumab.
Methods

Patients

We generated a prospective cohort of patients with encephalitis at Seoul National University Hospital and analyzed patients with autoimmune encephalitis after the use of a PD-L1 inhibitor (atezolizumab) from August 2016 to September 2019. Two expert neurologists in autoimmune meningoencephalitis (S-T.L. and H.C.) determined the relationship between atezolizumab and encephalitis based on the subacute development of CNS-irAEs and the diagnostic criteria for autoimmune encephalitis.20 The association between ICI use and the development of atezolizumab, seven of whom developed subacute encephalitis after atezolizumab administration. Two patients could not be enrolled in the current HLA study because DNA samples were not available (due to technical failure of DNA extraction for one patient, and the other patient did not provide consent for the study). Accordingly, a total of five patients were enrolled in the analysis, and their clinical characteristics are summarized in Table 1 and Fig 1. All patients had score 7 (probable) in the Naranjo adverse drug reaction probability scale.21 The initial symptoms, such as fever, fatigue, and headache, developed at days 5–15 after atezolizumab administration and progressed to decreased consciousness at days 15–16. Two patients had seizures. All the patients also had systemic irAEs. MRI showed diffuse leptomeningeal enhancement indicating meningitis and T2 high signals in the neocortex (patients 2, 3, and 5) (Fig. 2). CSF showed pleocytosis and increased protein levels. Four patients (Patient 1–4) were checked for paraneoplastic antibodies against amphiphysin, CRMP5, Ma2, Ri, Yo, Hu, Recoverin, Sox-1, Titin, Zic4, and glutamic-acid-decarboxylase-65, which were all negative. Patient 2 was tested for antibodies against NMDA-R, leucine-rich-gliaoma-inactivated 1 (LGI-1), CASPR2, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic-acid-receptor (AMPAR), dipeptidyl-peptidase-like protein 6 (DPPX), and γ-aminobutyric-acid-receptor-B (GABAB), which were all negative.

After treatment with immunotherapy, mainly with steroids (methylprednisolone 1 g daily for 5 days) and intravenous immunoglobulin (IVIG, 2 g/kg over 5 days), or with rituximab and tocilizumab in some serious patients (patients 2 and 3), consciousness was recovered in patients with specific HLA types and CNS-irAEs. Calibration for multiple tests was performed by multiplying the P-value by the number of alleles detected at each HLA locus: 44 for the HLA-B alleles and 22 for the HLA-C alleles (Bonferroni method). Statistical analysis was performed using SPSS version 18 (SPSS Inc., Chicago, IL, USA), and a two-sided P-value < 0.05 was considered significant.

Data Availability Statement

Individual participant data that underline the results reported in this article will be available from the corresponding author on request, in anonymized form.

Results

Patient characteristics

During the study period, a total of 290 patients received atezolizumab, seven of whom developed subacute encephalitis after atezolizumab administration. Two patients could not be enrolled in the current HLA study because DNA samples were not available (due to technical failure of DNA extraction for one patient, and the other patient did not provide consent for the study). Accordingly, a total of five patients were enrolled in the analysis, and their clinical characteristics are summarized in Table 1 and Fig 1. All patients had score 7 (probable) in the Naranjo adverse drug reaction probability scale. The initial symptoms, such as fever, fatigue, and headache, developed at days 5–15 after atezolizumab administration and progressed to decreased consciousness at days 15–16. Two patients had seizures. All the patients also had systemic irAEs. MRI showed diffuse leptomeningeal enhancement indicating meningitis and T2 high signals in the neocortex (patients 2, 3, and 5) (Fig. 2). CSF showed pleocytosis and increased protein levels. Four patients (Patient 1–4) were checked for paraneoplastic antibodies against amphiphysin, CRMP5, Ma2, Ri, Yo, Hu, Recoverin, Sox-1, Titin, Zic4, and glutamic-acid-decarboxylase-65, which were all negative. Patient 2 was tested for antibodies against NMDA-R, leucine-rich-gliaoma-inactivated 1 (LGI-1), CASPR2, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic-acid-receptor (AMPAR), dipeptidyl-peptidase-like protein 6 (DPPX), and γ-aminobutyric-acid-receptor-B (GABAB), which were all negative.

After treatment with immunotherapy, mainly with steroids (methylprednisolone 1 g daily for 5 days) and intravenous immunoglobulin (IVIG, 2 g/kg over 5 days), or with rituximab and tocilizumab in some serious patients (patients 2 and 3), consciousness was recovered in

HLA genotyping

We extracted genomic DNA from the patients’ blood and performed HLA genotyping. The genotype DNA sequencing of the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQBI genes of each subject was analyzed using direct DNA sequence analysis according to an established protocol (Biowithus, Seoul, Korea). The subjects were analyzed at the 4-digit allele level. Reported HLA frequencies in the Korean population were used as a control group.23

Statistical analysis

For statistical analysis, we used a control group of HLA genotypes from 485 Korean general populations. For each HLA type, odds ratios with 95% confidence intervals were calculated. The Fisher extract test was used to correlate...
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|-----------|-----------|-----------|-----------|-----------|
| **Sex/Age** | F/37 | F/53 | F/70 | M/42 | F/60 |
| **Type of cancer** | Breast cancer | Bladder cancer | Bladder cancer | Bladder cancer | Breast cancer |
| **Previous chemotherapy** | None | Gemcitabine, cisplatin, paclitaxel, pemetrexed cyclophosphamide, palbociclib | Bacillus Calmette–Guerin (BCG), gemcitabine, cisplatin | Cobimetinib | Bacillus Calmette–Guerin (BCG), gemcitabine, cisplatin, Doxorubicin, |
| **Combined chemotherapy** | Cobimetinib | None | None | Cobimetinib | Fulvestrant, ipatasertib |
| **Clinical phenotype** | Encephalitis (fever, altered mentality) | Encephalitis (fever, seizure, cranial nerve palsy), axonal Guillain–Barre syndrome (limb weakness, facial palsy) | Encephalitis (fever, seizure, altered mentality), Guillain–Barre syndrome-motor dominant (limb weakness, facial palsy), myelitis (incontinence, saddle anesthesia) | Encephalitis (fever, altered mentality) | Encephalitis (fever, altered mentality) |
| **Systemic irAE** | Skin rash, hepatitis, pneumonitis | Hepatitis, pneumonia | Skin rash | Diarrhea | Skin rash, hepatitis, mucositis, eosinophilia |
| **Seizure** | (-) | (+) | (+) | (-) | (-) |
| **EEG abnormality** | Not performed | Diffuse slowing | Diffuse slowing | Diffuse slowing | Diffuse slowing |
| **From atezolizumab to mental change (day)** | 15 | 18 | 15 | 15 | 16 |
| **CSF findings** | Pleocytosis (WBC 54/µl, poly 51%, lympho 40%, other 7%), high protein (111 mg/dL), glucose (81mg/dL) | Pleocytosis (WBC 222/µl, poly 38%, lympho 15%, other 47%), high protein (1000 mg/dL), glucose (81mg/dL) | Pleocytosis (WBC 30/µl, poly 20%, lympho 20%, other 60%), high protein (358 mg/dL), glucose (79mg/dL) | Pleocytosis (WBC 30/µl, poly 20%, lympho 20%, other 60%), high protein (358 mg/dL), glucose (79mg/dL) | Pleocytosis (WBC 135/µl, poly 5%, lympho 50%, other 45%), high protein (377 mg/dL), glucose (86mg/dL) |
| **MRI findings** | Diffuse leptomeningeal enhancement | T2 high signals in limbic and brainstem areas with leptomeningeal enhancement | T2 high signals in white matter (right> left) and T6 – T9 spinal cord | No significant abnormality | T2 high signals in the left medial frontal gyrus with leptomeningeal enhancement |
| **Immunotherapy against irAE** | Steroid, immunoglobulin | Steroid, immunoglobulin, rituximab, tocilizumab | Steroid, immunoglobulin, rituximab | Steroid, immunoglobulin | Steroid, immunoglobulin |
| **Time required to recover consciousness (days)** | 2 | 6 | 4 | 5 | 2 |
| **Initial mRS** | 5 | 5 | 5 | 5 | 5 |
| **mRS at 1 month** | 2 | 5 | 5 | 2 | 2 |
| **mRS at 3 months** | 2 | 5 | 5 | 2 | 2 |
| **HLA-B*27:05** | Negative | Positive | Positive | Positive | Negative |
| **HLA-C*01:02** | Negative | Positive | Positive | Positive | Positive |
2 ~ 6 days. However, disability measured by mRS scores remained unchanged.

**HLA genotypes of the patients with CNS-irAEs**

After analyzing the full HLA genotypes of the five patients and comparing them to those in the normal Korean population, we found that two HLAs were increased in the CNS-irAE patients. The first genotype was HLA-B*27:05, which was identified in the three patients (60%) with the most severe clinical phenotype (patients 2, 3, and 4). In the Korean population, HLA-B27 is present in only 3.1% of individuals, and HLA-B*27:05 is present in only 2.5% of individuals. After Bonferroni correction, HLA-B*27:05 was significantly associated with CNS-irAEs (corrected $P < 0.001$, odds ratio 59, 95% CI = 9.0 ~ 386.9) (Table 2). HLA-C1*01:02 was also found in 4 of 5 patients (80%, patients 2, 3, 4, and 5). HLA-C1*01:02 is present in 18% of the Korean population. The association between HLA-C1*01:02 and CNS-irAEs was not significant after Bonferroni correction (corrected $P = 0.088$, odds ratio 18.8, 95% CI = 2.0 ~ 170.5). The Table S1 provides the detailed HLA genotypes.

**Clinical phenotypes of patients with HLA-B*27:05**

The three patients (patients 2, 3, and 4) with HLA-B*27:05 developed encephalitis with altered mentality, two of whom were considered severe and showed decreased mentality or myelitis (mRS = 4). Patient 2 had meningitis, limbic and brainstem encephalitis, cranial nerve palsies, and Guillain–Barre syndrome. This patient received ICU care because of seizures, and MRI showed multiple T2 signal changes in the brainstem. Steroids and IVIG were not sufficient for treatment, and rituximab and tocilizumab were added. The patient remained disabled and died after 7 months due to cancer progression. Patient 3 had encephalitis, myelitis, and Guillain–Barre syndrome. Myelitis involved the T6 ~ T9 levels, and the patient remained paraplegic even after steroid, IVIG, and rituximab treatment. Patient 4 had encephalitis and improved 5 days after steroid and IVIG treatment. None
of the three patients with HLA-B*27:05 had experienced any symptoms of ankylosing spondylitis.

**Discussion**

Here, we found that three in five patients with CNS-irAEs caused by atezolizumab have the HLA-B*27:05 genotype. The population frequency of HLA-B*27:05 is only 2.5% in Koreans and 3.7% in the United States and European Caucasians. The expected number of HLA-B*27:05 in 290 atezolizumab-treated Korean patients is about seven (7.25). We found that three had CNS-irAE. In addition, the patients with HLA-B*27:05 had a severe phenotype of the CNS-irAE. Because CNS-irAEs are life-threatening when develops, the finding has significant clinical implications and warrant in-depth multicenter investigations to determine whether serious CNS-irAEs can be prevented if HLA-B*27:05 is included in the screening test before the use of ICPIs.

Encephalitis induced by irAEs causes seizures, altered mentality, and memory loss. Encephalitis induced by irAE can be diagnosed by the clinical phenotype, MRI, and exclusion of infectious encephalitis. Sometimes, autoantibodies such as anti-NMDAR and anti-Hu can be detected. Treatment of encephalitis induced by irAEs includes steroids, IVIG and more advanced

**FIGURE 2.** Lesions on MRI. Upper row: Diffusion-weighted images. Middle row: Fluid-attenuated Inversion Recovery Sequence. Lower row: Gadolinium-enhanced T1-weighted images, spine MRI of Patient 3: Ill-defined T2 hyperintense intramedullary abnormality of the spinal cord at the T6 – T9 level.

**Table 2.** Frequency differences in selected alleles in CNS-irAE patients versus healthy controls.

| HLA allele frequency | CNS-irAE patient- no. (%) | Healthy controls- no. (%) | OR(95% CI)          | P     | Pc     |
|----------------------|---------------------------|---------------------------|---------------------|-------|-------|
| HLA-B*27:05          | 3/5 (66%)                 | 12/485 (2.5%)             | 59.1 (9.0 – 386.9)  | <0.001| <0.001|
| HLA-C1*01:02         | 4/5 (80%)                 | 89/485 (18%)              | 18.8 (2.0 – 170.5)  | 0.004 | 0.088 |

*HLA data are from five CNS-irAE patients and 485 healthy controls. Pc: Pc values are the results of modifications using Bonferroni’s method for multiple comparisons. For correction, P-values were multiplied by the number of alleles detected for each HLA locus. HLA = human leukocyte antigen.
immunomodulators such as rituximab and tocilizumab. While most patients respond to steroid and guidelines suggest to use steroid first, patients with Guillain–Barre syndrome need IVIG and those with severe refractory diseases could be controlled by combination immunotherapy using biological immunosuppressants, as we did in our patient #2 and #3. Although CNS-irAEs are possible with all ICPIs, including CTLA-4, PD-1, and PD-L1 inhibitors, this study analyzed a PD-L1 inhibitor because autoimmune encephalitis cases by the other drugs were rare in our institution. All five patients in this study showed the typical clinical presentation of autoimmune encephalitis, which could be explained most likely by the use of atezolizumab.

 Originally, the HLA-B*27:05 genotype was associated with ankylosing spondylitis and other systemic inflammatory diseases, such as psoriasis, inflammatory bowel disease, and reactive arthritis. While the exact mechanism by which HLA-B*27 induces inflammatory disease is not exactly known, HLA-B27 may be an antigen pocket for molecular mimicry and may be recognized by CD4 T cells to initiate a proinflammatory response through an unfolded protein response. The self-peptide displayed by HLA-B27 may be the target of autoreactive CD8 T cells. In addition, the HLA-B*27:05 genotype influences the antitumor efficacy of ICPIs.

 If patients treated with atezolizumab have the HLA-B*27:05 genotype, the risk of CNS-irAEs can be discussed. In similar, HLA-B*15:02 and HLA-A*31:01 increase the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis in patients treated with carbamazepine or oxcarbazepine. Thus the guideline by the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends not to use carbamazepine if these HLAs are detected. Similarly, HLA-DRB1*11:01 might be associated with pruritus due to ICPI use. In this study, Ali et al. analyzed 102 patients who received IC1 treatment with CTLA-4 and PD-1, and the most common single side effect was pruritus. They found significant associations between HLA-DRB1*11:01 and pruritus and between HLA-DRB1*03:01 and colitis.

 However, we have no data regarding whether HLA-B*27:05 is associated with other systemic irAEs caused by atezolizumab or whether HLA-B*27:05 increases the risk of irAEs induced by other ICPIs, such as CTLA-4 or PD-1 inhibitors. In addition, because patients with HLA-B27 or ankylosing spondylitis have an slightly increased risk of hematologic malignancy or systemic cancer, it is also necessary to analyze the prevalence of HLA-B27 in the control cancer patients. Until then, our data suggest that HLA-B*27:05 might be a risk factor gene for CNS-irAEs induced by atezolizumab. Because the current case number in our study is limited, prospective systematic analysis of HLA genotypes in patients receiving ICPIs is necessary to clarify the association and to prevent disabling adverse effects by autoimmune encephalitis.

 Acknowledgment

 This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (2019R1A2C1009003).

 Authors’ Contributions

 H.C. and S.-T.L. involved in the study concept, design, and experiments. All authors involved in data acquisition and analysis, drafting of the manuscript, and figures. All authors participated in the revision of the manuscript and approved the final version.

 Conflicts of Interest

 Patent pending for the HLA analysis to predict CNS-irAE (H.C., and S.-T.L.). Seok-Ah Im received a research grant from AstraZeneca, Pfizer and Roche outside of the current work and have advisory role for AstraZeneca, Amgen, Eisai, Hanmi Corp. Lilly, Novartis, Pfizer, and Roche outside of the current work. Soon-Tae Lee have an advisory role for Ono Pharmaceuticals and received research grants from GC Pharma outside of the current work.

 References

 1. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346–1353.
 2. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139–148.
 3. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563–580.
 4. Renton AE, Pliner HA, Provenzano C, et al. A genome-wide association study of myasthenia gravis. JAMA Neurol 2015;72:396–404.
 5. Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 2015;52:307–308.
6. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-cTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013;8:e53745.

7. Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol 2013;13:278–280.

8. Kim A, Keam B, Cheun H, et al. Immune-checkpoint-inhibitor-induced severe autoimmune encephalitis treated by steroid and intravenous immunoglobulin. J Clin Neurol 2019;15:259–261.

9. Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016;73:928–933.

10. Papadopoulos KP, Romero RS, Gonzalez G, et al. Anti-hu-alkaline phosphatase antibody secondary to pembrolizumab therapy. J Neuroimmunol 2017;305:16–18.

11. Leonetti A, Weyer B, Mazzaschi G, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat 2019;46:100644.

12. Ettinger DS, Wood DE, Aggarwal C, et al. Anti-hu-association autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 2018;23:118–120.

13. Brown MP, Hisaria P, Hsieh AH, et al. Anti-human T cell leukemia-1 antibody-induced severe autoimmune encephalitis treated by steroid and intravenous immunoglobulin. J Clin Neurol 2019;15:259–261.

14. Papadopoulos KP, Romero RS, Gonzalez G, et al. Antibody against hu-alkaline phosphatase secondary to pembrolizumab therapy. J Neuroimmunol 2017;305:16–18.

15. Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016;73:928–933.

16. Saleh R, Taha RZ, Sasidharan Nair V, et al. PD-L1 blockade by atezolizumab downregulates signaling pathways associated with tumor growth, metastasis, and hypoxia in human triple negative breast cancer cells. Oncoimmunology 2019;8:e1624128.

17. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.

18. Levine JJ, Somer RA, Hosoya H, Squillante C. Atezolizumab-induced encephalitis in metastatic bladder cancer: a case report and review of the literature. Clin Genitourin Cancer 2017;15:e847–e849.

19. Laserna A, Tummala S, Patel N, et al. Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature. SAGE Open Med. Case Reports 2018;6:2050313X1879242.

20. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.

21. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981;30:239–245.

22. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36:1714–1768.

23. Moon J, Park H-K, Chu K, et al. The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population. Epilepsia 2015;56:e161–e167.

24. Yoon JH, Shin S, Park MH, et al. HLA-A, -B, -DRB1 allele frequencies and haplotypic association from DNA typing data of 7096 Korean cord blood units. Tissue Antigens 2010;75:170–173.

25. Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens 2005;65:437–447.

26. Gragert L, Madbouly A, Freeman J, Maiers M. Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Hum Immunol 2013;74:1313–1320.

27. Martins F, Sykiotis GP, Maillard M, et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol 2019;20:e54–e64.

28. Chen B, Li J, He C, et al. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review). Mol Med Rep 2017;15:1943–1951.

29. Lahesmaa R, Skurnik M, Vaara M, et al. Molecular mimicry between HLA B27 and Yersinia, Salmonella, Shigella and Klebsiella within the same region of HLA class I helices. Clin Exp Immunol 1991;86:399–404.

30. Ferreira A, Monteiro M, Vita P, et al. Post-infectious arthritis and reactive arthritis. Infection and Autoimmunity. Elsevier 2015;807–828.

31. Hermann E, Meyer zum Bäsenfeld C, Fleischer B, Yu DT. HLA-B27-restricted CD8+ T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993;342:646–650.

32. Zambrano-Zaragoza JF, Agraz-Cibrian JM, Gonzalez-Reyes C, et al. Ankylosing spondylitis: from cells to genes. Int J Inflam 2013;2013:1–16.

33. Cauli A, Shaw J, Giles J, et al. The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-

© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
B*27:09. Rheumatol. (United Kingdom) 2013;52:1952–1962.
34. Hung S-I, Chung W-H, Jee S-H, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297–306.
35. Chen CB, Hsiao YH, Wu T, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology 2017;88:78–86.
36. Yip VL, Marson AG, Jorgensen AL, et al. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: A systematic review. Clin Pharmacol Ther 2012;92:757–765.
37. Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical Pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharmacol Ther 2018;103:574–581.
38. Hasan Ali O, Berner F, Bomze D, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2019;107:8–14.
39. Au WY, Hawkins BR, Cheng N, et al. Risk of haematological malignancies in HLA-B27 carriers. Br J Haematol 2001;115:320–322.
40. Chang CC, Chang CW, Nguyen PAA, et al. Ankylosing spondylitis and the risk of cancer. Oncol Lett 2017;14:1315–1322.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. HLA genotypes of the patients.